CCXI Description — ChemoCentryx, Inc.

ChemoCentryx is a biopharmaceutical company focused on the development of medications targeting inflammatory disorders, autoimmune diseases and cancer. Each of Co.'s drug candidates is designed to selectively block a specific chemoattractant receptor. Co. is preparing for a potential commercial launch of avacopan for the treatment of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Co. is also developing avacopan for the treatment of severe (Hurley Stage III) hidradenitis suppurativa. CCX559 is Co.'s orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1, which Co. is developing for the treatment of various cancers.

Company Name: 
ChemoCentryx, Inc.
Number of ETFs Holding CCXI: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   CCXI Weight   CCXI Amount 
 XBI   0.85%   $61,753,684         
 VTI   0.00%   $23,704,710         
 VB   0.01%   $20,752,668         
 IWM   0.03%   $20,042,352         
 VBK   0.03%   $13,143,458         
 VXF   0.01%   $11,715,804         
 IWN   0.06%   $8,807,080         
 IBB   0.06%   $6,811,317         
 LABU   0.46%   $3,044,852         
 VHT   0.01%   $2,444,880         
List of all 31 ETFs holding CCXI »
Quotes delayed 20 minutes

Hold (2.50 out of 4)
1st percentile
(ranked lower than approx. 99% of all stocks covered)

Analysts Forecast:
CCXI Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding CCXI | ChemoCentryx, Inc. | ETF Channel |

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.